Aug 2026· Oncology Research· Vol 34, pp. 1-10· 0 citations· 166 references
Medicine
TL;DR
This review summarizes the major sources and regulation of mtROS, their involvement in cancer-associated signaling pathways, mitochondrial calcium dynamics, metabolic adaptations, and resistance to anticancer therapies, and discusses current and emerging mitochondrial- targeting strategies aimed at exploiting mtROS signaling to improve cancer treatment outcomes.
Abstract
Mitochondria are central regulators of cellular metabolism and survival and play a pivotal role in cancer development and progression through the production of reactive oxygen species (ROS), control of calcium homeostasis, regulation of autophagy, and modulation of cell death pathways. Mitochondria-derived ROS (mtROS) act as signaling mediators that influence tumor initiation, proliferation, metabolic reprogramming, metastasis, and therapeutic resistance by altering redox homeostasis, damaging mitochondrial DNA, and reshaping the tumor microenvironment. In addition to meeting the bioenergetic and biosynthetic requirements of rapidly proliferating cancer cells, mitochondrial metabolism modulates immune responses and supports cancer cell adaptation to hypoxia and nutrient deprivation. Accumulating evidence also highlights the dual role of mtROS, which can promote tumor progression at moderate levels yet trigger oxidative stress-induced cell death when excessively increased, making mitochondrial redox signaling an attractive therapeutic target. This review summarizes the major sources and regulation of mtROS, their involvement in cancer-associated signaling pathways, mitochondrial calcium dynamics, metabolic adaptations, and resistance to anticancer therapies, and discusses current and emerging mitochondrial-targeted strategies aimed at exploiting mtROS signaling to improve cancer treatment outcomes.
This review explores the mechanistic interplay between mitochondrial dynamics and cancer bioenergetics, emphasising how these processes contribute to drug resistance and focus on emerging therapeutic strategies targeting mitochondrial fusion and fission that offer promising potential to restore chemosensitivity and dis...
Varsha Johariya, Vaibhav Singh, Rakesh Kore et al.· Mini-Reviews in Medical Chem...· 0 citations
Recent studies demonstrate promising therapeutic targets for mitochondrial dysfunction and highlight the need for research in mitochondrial function to change the therapeutic landscape in the management of mitochondrial dysfunction-associated diseases.
Olufemi Akintayo Akinkunmi, Feyikemi Funmilayo Araba, J. A. Chukwudebelu et al.· Frontiers in Cell and Develo...· 0 citations
Gastric cancer (GC) remains a major global health burden and is associated with high mortality worldwide. Current treatment integrates surgery, perioperative or systemic chemotherapy, molecularly targeted therapy, and immune checkpoint blockade; however, efficacy is frequently limited by intratumoral heterogeneity, met...
Hsi-Lung Hsieh, Ming-Chin Yu, Hui-Ching Tseng et al.· Journal of Cancer· 0 citations
Oxidative stress good or evil? Oxidative stress occurs when the balance between reactive oxygen species (ROS) and antioxidant defenses shifts toward an excess of ROS; while essential in physiological processes, it plays a context-dependent role in cancer, contributing to both the promotion and inhibition of tumorigenes...
María Escribano-Cebrián, M. Bataller, M. Biasini et al.· Redox Biology· 0 citations